Quick Answer
Taysha Gene Therapies, Inc. reported Net Income Loss of -$109.00 million for the year ending 2025.
- Taysha Gene Therapies, Inc. showed a decrease of -22.1% in Net Income Loss from 2024 to 2025.
- This data is from Taysha Gene Therapies, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: -$31.0 thousand | Q4 2019: -$1.12 million | Q1 2020: -$5.43 million | Q2 2020: -$21.22 million | Q3 2020: -$15.04 million | Q1 2021: -$32.02 million | Q2 2021: -$40.93 million | Q3 2021: -$51.19 million | Q1 2022: -$50.32 million | Q2 2022: -$34.09 million | Q3 2022: -$26.53 million | Q1 2023: -$17.62 million | Q2 2023: -$24.60 million | Q3 2023: -$117.09 million | Q1 2024: -$24.06 million | Q2 2024: -$20.93 million | Q3 2024: -$25.52 million | Q1 2025: -$21.53 million | Q2 2025: -$26.88 million | Q3 2025: -$32.73 million.
- Over the full 6 years of available data (2020 to 2025), Taysha Gene Therapies, Inc.'s Net Income Loss has declined by 81.6%.
- Historical annual values: Fiscal year 2025: -$109.00 million | Fiscal year 2024: -$89.30 million | Fiscal year 2023: -$111.57 million | Fiscal year 2022: -$166.01 million | Fiscal year 2021: -$174.52 million | Fiscal year 2020: -$60.01 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: